www.fdanews.com/articles/124178-fda-accepts-javelin-8217-s-submission-files-new-drug-application-for-dyloject
FDA Accepts Javelin’s Submission, Files New Drug Application for Dyloject
February 2, 2010
Myriad Pharmaceuticals Inc. Tuesday announced that the
U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’ submission
and filed a New Drug Application for Dyloject, an investigational, injectable NSAID for the management of acute moderate-to-severe postoperative pain in
adults.
CNNMoney
CNNMoney